Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (21-30 of 127) with videos related to

Pageof 13
Sort By:
Cancer Metastasis Reviews|June 28, 2012
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destinyKenichi Suda, Hiroshi Mizuuchi, Yoshihiko Maehara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
EGFR T790M mutation: a double role in lung cancer cell survival?Kenichi Suda, Ryoichi Onozato, Yasushi Yatabe, et al.
Lancet (London, England)|September 7, 2016
New and emerging targeted treatments in advanced non-small-cell lung cancerFred R Hirsch, Kenichi Suda, Jacinta Wiens, et al.
Expert Review of Anticancer Therapy|July 14, 2017
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanismsKenichi Suda, Christopher J Rivard, Tetsuya Mitsudomi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2010
Analysis of ERBB4 mutations and expression in japanese patients with lung cancerKenji Tomizawa, Kenichi Suda, Ryoichi Onozato, et al.
International Journal of Cancer|January 25, 2014
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptorKenichi Suda, Hiroshi Mizuuchi, Katsuaki Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 20, 2016
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the BenchKenichi Suda, Paul A Bunn, Christopher J Rivard, et al.
Thoracic Cancer|August 15, 2015
Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a caseHiroshi Mizuuchi, Kenichi Suda, Hirokazu Kitahara, et al.
Lung Cancer (Amsterdam, Netherlands)|December 3, 2011
Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutationKenichi Suda, Kenji Tomizawa, Hirotaka Osada, et al.
Thoracic Cancer|October 8, 2015
Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resectionKenji Tomizawa, Kenichi Suda, Toshiki Takemoto, et al.
Pageof 13

Showing results (21-30 of 127) with videos related to

Sort By:
Pageof 13
Cancer Metastasis Reviews|June 28, 2012
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destinyKenichi Suda, Hiroshi Mizuuchi, Yoshihiko Maehara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
EGFR T790M mutation: a double role in lung cancer cell survival?Kenichi Suda, Ryoichi Onozato, Yasushi Yatabe, et al.
Lancet (London, England)|September 7, 2016
New and emerging targeted treatments in advanced non-small-cell lung cancerFred R Hirsch, Kenichi Suda, Jacinta Wiens, et al.
Expert Review of Anticancer Therapy|July 14, 2017
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanismsKenichi Suda, Christopher J Rivard, Tetsuya Mitsudomi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2010
Analysis of ERBB4 mutations and expression in japanese patients with lung cancerKenji Tomizawa, Kenichi Suda, Ryoichi Onozato, et al.
International Journal of Cancer|January 25, 2014
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptorKenichi Suda, Hiroshi Mizuuchi, Katsuaki Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 20, 2016
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the BenchKenichi Suda, Paul A Bunn, Christopher J Rivard, et al.
Thoracic Cancer|August 15, 2015
Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a caseHiroshi Mizuuchi, Kenichi Suda, Hirokazu Kitahara, et al.
Lung Cancer (Amsterdam, Netherlands)|December 3, 2011
Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutationKenichi Suda, Kenji Tomizawa, Hirotaka Osada, et al.
Thoracic Cancer|October 8, 2015
Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resectionKenji Tomizawa, Kenichi Suda, Toshiki Takemoto, et al.
Pageof 13